Strandtx
Boston, US Β· Founded 2017 Β· 124 employees on LinkedIn Β· 8 known investors
Find your way into Strandtx
856 people in our graph share verified history with the Strandtx team β schools, employers, funds. One of them is your warm intro.
Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases. The company has created an mRNA platform with cell-selective targeting capabilities to deliver therapeutic payloads within the body.
Also known as Strand Β· Strand Therapeutics Β· Strand Therapeutics Inc. Β· StrandTX
Founders & leadership
Strandtx was founded in 2017 by Jacob Becraft, Tasuku Kitada, Ron Weiss, and Darrell J. Irvine.
Board
Investors Β· 8
Also in the syndicate Β· 3
Valuation Β· disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed β follow each entry's link for the claim.
Company profile
researched Aug 2026Strand Therapeutics (StrandTX) is a Boston-based, clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases. The company spun out of MIT and was founded by biological engineers from the institute. Its approach combines engineered lipid nanoparticle delivery with mRNA constructs that carry intracellular logic circuits, so that a therapeutic protein is expressed in target cells and switched off in off-target tissue.
The platform is organized around three stated technical problems in genetic medicine. SignalPath LNPs are engineered for on-target tissue delivery beyond the liver, including tumors and immune cells. SignalLock RNA uses microRNA-sensing circuits to restrict payload expression to target tissues and deactivate it elsewhere, which the company presents as enabling systemic administration in a standard healthcare setting. SignalScript RNA covers self-replicating and circular RNA constructs intended to increase potency and durability of expression.
The pipeline is led by STX-001, an LNP-encapsulated self-replicating mRNA encoding interleukin-12 (IL-12) that is injected directly into tumors; it entered a Phase 1 dose-escalation trial in advanced solid tumors, with first patient dosed in May 2024 and initial data presented at ASCO in 2025. STX-003 is a systemically delivered program using SignalLock RNA and liver-avoidance circuits, guided toward the clinic in 2026. STX-005 is a preclinical in vivo CAR-T approach for autoimmune diseases and blood cancers, supported by circular RNA CAR work presented at ASGCT.
Founding story
The company originated at MIT, spinning out in 2017 and founded by biological engineers from the institute who set out to build an mRNA programming language and logic-circuit platform for controlling where, when and how strongly therapeutic proteins are expressed.
Business model
Strand develops proprietary mRNA therapeutics in-house as a clinical-stage biotechnology company, advancing its own lead programs while positioning its programmable genetic-circuit platform for partnerships with pharmaceutical companies. Sacra characterizes the model as B2B, oriented toward pharmaceutical companies and healthcare systems, with corporate venture investments from Regeneron, Amgen and Eli Lilly described as potential future licensing or collaboration channels. Rather than manufacturing protein biologics, the company packages mRNA instructions in lipid nanoparticles so that patient cells produce the therapeutic protein locally, which is presented as a route to lower manufacturing complexity and lower dosing requirements.
Traction
STX-001 received IND clearance in January 2024, dosed its first patient in May 2024, and reported initial first-in-human Phase 1 results at the 2025 ASCO Annual Meeting. Phase 1 data in 22 checkpoint-refractory patients included one complete response and multiple partial responses with no dose-limiting toxicities; dose expansion began in August 2025, with plans for Phase 2 and checkpoint-inhibitor combination cohorts. STX-003 is guided to first-in-human evaluation in 2026, and preclinical in vivo CAR-T data were slated for presentation at ASGCT 2026. The company has raised a $153 million Series B led by Kinnevik (August 2025) and previously brought its Series A to $97 million (November 2022). Third-party estimates place headcount at approximately 121 employees.
Latest developments
In April 2026 Strand announced the appointment of Kunal Bhatia as Chief Financial Officer and plans to present preclinical data on its programmable mRNA in vivo CAR-T platform at the 29th ASGCT Annual Meeting. In December 2025 it added Jeb Keiper to its board and announced a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company also reports awards including Fast Company Most Innovative Companies (2026), Biotech Breakthrough Startup of the Year (2026) and Boston Business Journal Best Places to Work (2025 and 2026).
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Strand competes in mRNA therapeutics against incumbents Moderna and BioNTech, which have larger manufacturing and clinical development infrastructure and are expanding into oncology, and against synthetic-biology and circuit-programming companies such as Senti Biosciences (programmable cell therapy) and Orna Therapeutics (circular mRNA). Traditional immunotherapy developers including Immunocore, Adaptimmune and TCR2 Therapeutics compete for overlapping patient populations and trial sites. Strand's stated differentiator relative to first-generation mRNA platforms is programmable targeting that allows delivery of potent immunostimulants such as IL-12 with reduced systemic toxicity; it has clinical validation with STX-001 that circuit-focused peers are described as lacking.
Strand's positioning rests on cell-selective, programmable control of mRNA expression: microRNA-sensing circuits that encrypt payloads so they express only in target tissue, LNPs engineered to reach tissues beyond the liver, and self-replicating or circular RNA for greater potency and durability. Together these are presented as enabling systemic administration of payloads that would be too toxic with conventional delivery, and as a plug-and-play platform applicable across payloads and indications.
Technology
The core technology couples engineered lipid nanoparticles (SignalPath LNPs) for tissue-selective delivery with mRNA that carries logic circuits acting as cellular sensors. MicroRNA-sensing elements (SignalLock RNA) verify the molecular environment of a cell before the payload is expressed, deactivating expression in off-target tissue; STX-003 adds liver-avoidance circuitry for systemic dosing. SignalScript RNA covers self-replicating and circular RNA formats intended to extend and strengthen protein expression. In STX-001, self-replication is triggered when microRNA sensors detect a tumor environment, producing IL-12 for several weeks to recruit and activate T cells against the injected tumor and distant metastases. Preclinical work extends the circuits to in vivo CAR-T generation and circular RNA CAR constructs.
Go-to-market
Strand advances its lead oncology programs internally through its own clinical trials and scientific conference disclosures (AACR, ASCO, ASGCT, SITC), while cultivating pharmaceutical partnerships; investments from the corporate venture arms of Regeneron, Amgen and Eli Lilly are described as potential future licensing or collaboration routes.
Patients with advanced solid tumors, blood cancers and autoimmune diseases are the ultimate treatment population; commercially the company orients toward pharmaceutical partners and healthcare systems for co-development, licensing and collaboration.
Geography
Headquartered in Boston, Massachusetts, United States, with its R&D footprint based there.
History
Strand was founded in 2017 as a spin-out of MIT by biological engineers from the institute. Early financing included a seed round led by Playground Global in 2019. In November 2022 the company announced a Series A1 that brought its total Series A to $97 million, with Eli Lilly among the backers, and was named to Fierce Biotech's Fierce 15 that September. STX-001 obtained IND clearance in January 2024 and entered Phase 1 in solid tumors that May, with initial data presented at ASCO in May 2025. In August 2025 Strand closed a $153 million Series B led by Kinnevik and appointed Jason J. Luke as Chief Medical Officer; Kinnevik's Ala Alenazi joined the board. Later appointments included Prashant Nambiar's promotion to Chief Scientific Officer and Ethan Cash as SVP of portfolio management (November 2025), Jeb Keiper to the board (December 2025) and Kunal Bhatia as Chief Financial Officer (April 2026).
Compiled by commissioned research from 4 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Founder mafia
2 people who came through Strandtx went on to found or lead other companies.
Competitors Β· 3
by search overlap
Companies competing with Strandtx for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 18
launches, deals, and filingsStrand announced it would present preclinical data on its programmable mRNA in vivo CAR-T platform at the 29th American Society of Gene & Cell Therapy Annual Meeting.
Series B financing led by Kinnevik, with participation from Iconiq, Playground Global, Regeneron Ventures, Amgen and Eli Lilly, to advance the programmable mRNA therapeutic pipeline; reported valuation of approximately $550 million.
$153M source β
Strand initiated dose expansion for STX-001 and outlined plans to progress into Phase 2 and add checkpoint inhibitor combination cohorts.
Data from the Phase 1 dose escalation of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors.
Strand received IND clearance for programmable mRNA therapy STX-001 to treat solid tumors.
Strand announced a Series A1 extension, reported at $45 million with backing from Eli Lilly, bringing the total round to $97 million.
$45M source β
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 4
primary sources listed
- Strandtxstrandtx.com Β· web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Strandtx do?
- Strand Therapeutics is a clinical-stage biotech developing programmable mRNA therapeutics for solid tumors and autoimmune diseases.
- Who founded Strandtx?
- Strandtx was founded by Jacob Becraft, Tasuku Kitada, Ron Weiss, Darrell J. Irvine in 2017.
- Who are Strandtx's investors?
- Strandtx's investors include Atinum Investment Co. Ltd., FPV, LG Technology Ventures, Playground Global, Starlight Ventures.
- Where is Strandtx headquartered?
- Strandtx is headquartered in Boston, US.